STOCKS TELEGRAPH

Tag: NuCana

  • NuCana (NCNA) Sees Pre-Hour Stock Surge Following New Patent Issuance

    NuCana (NCNA) Sees Pre-Hour Stock Surge Following New Patent Issuance

    After a new patent issue was announced, NuCana plc (NASDAQ: NCNA) is a notable share-price increase today. As of the latest pre-market check, NCNA stock has jumped 18.69% to trade at $3.62 on the US stock charts. The surge in stock price is coming on the heels of a significant advance concerning the company’s anti-cancer drug, NUC-7738.

    New Patent Enhances NuCana’s Intellectual Property

    A fresh patent covering the composition of matter for NUC-7738 has been awarded to NuCana by the USPTO, the United States Patent and Trademark Office. This patent is an important complement to the more than 80 granted patents that NUC-7738 currently possesses as a strong foundation for its intellectual property. NuCana stressed the significance of this patent in securing the agent’s protection, especially as clinical studies progress.

    NCNA Shared Encouraging Clinical Trial Results

    Trial participants whose melanoma is resistant to PD-1 inhibitors are the primary target population. NuCana revealed encouraging findings at the European Society for Medical Oncology (ESMO) Congress 2024, demonstrating how NUC-7738 targets the tumor microenvironment and can sensitize previously resistant tumors to PD-1 inhibitor rechallenge.

    Of the twelve patients enrolled in the experiment, seventy-five attained disease control, and two showed partial responses. Remarkably, one patient demonstrated a 55% reduction in tumor size after progressing on two prior PD-1-based therapies. Additionally, seven patients maintained progression-free survival for over five months—exceeding the typical range of 2-3 months for this patient population.

    Future Prospects for NUC-7738

    NUC-7738 has demonstrated a positive safety profile when used in conjunction with pembrolizumab, in addition to its effectiveness. NuCana (NCNA) is pushing the development of NUC-7738 as a potential therapy for melanoma patients who have run out of other treatment choices, encouraged by these results. The company’s position in the cancer market is further strengthened by the recent patent issue, which lays a solid platform for future clinical and commercial success.

  • NuCana (NCNA) Stock Surges Pre-Market On Promising Clinical Trial Data

    NuCana (NCNA) Stock Surges Pre-Market On Promising Clinical Trial Data

    Shares of NuCana plc (NASDAQ: NCNA) are experiencing a remarkable surge this morning on the US stock charts following the release of promising clinical trial data. As of the latest pre-market session, NCNA stock risen by 180.31%, reaching $7.12.

    NuCana Shared Encouraging Phase 2 Study Results

    At the ESMO Congress, NuCana revealed the findings of their Phase 2 NuTide:701 research, which examined the use of NUC-7738 in conjunction with pembrolizumab for patients with metastatic melanoma who had previously encountered resistance or recurrence on PD-1 inhibitor treatment.

    Twelve patients made up the trial cohort, the majority of whom having received at least two lines of PD-1 inhibitor therapy before. Surprisingly, two of these patients reported Partial Responses, and 75% of them were able to control their condition. Notably, one patient had a 55% decrease in tumor volume after taking NUC-7738; this patient had previously progressed on ipilimumab with nivolumab.

    NCNA Observed Exceptional Survival Rates and Safety Profile

    Seven of the 12 patients showed a progression-free survival (PFS) time exceeding five months, a significant improvement compared to the typical 2-3 months PFS seen with current standard treatments. The combination of NUC-7738 and pembrolizumab also exhibited a favorable safety profile, further underscoring its potential as a viable therapeutic option.

    Mechanism of Action and Future Prospects

    NUC-7738’s efficacy in overcoming PD-1 resistance is attributed to its capacity to disrupt RNA polyadenylation, thereby altering gene expression within cancer cells and affecting the tumor microenvironment. Data from tumor biopsies before and after treatment revealed increased gene activity associated with antigen presentation and T-cell activation, supporting the hypothesis of NUC-7738’s effectiveness.

    The translational data suggest that the observed sensitization of previously resistant tumors to PD-1 inhibitors may extend beyond melanoma to other cancer types. NuCana (NASDAQ: NCNA) is optimistic about these findings and plans to share further development strategies for NUC-7738 in the near future.

  • NuCana plc (NCNA) Falls Despite Promising Outlook

    NuCana plc (NASDAQ: NCNA) is a British biopharmaceutical company that is fully geared to developing effective treatments against cancer. The company has, over the years, developed several products that are effective agents to administer to chemotherapy patients. An announcement made by the management, earlier this year, however, saw NCNA stock price crashing.

    A Look at NCNA

    NuCana plc (NCNA) holds a healthy pipeline that consists of both early and mid-stage trial candidates that each target a different cancerous condition. At present, at least 16 anti-cancer nucleoside drug treatments by NuCana have seen approval from the FDA. These are essentially chemotherapy agents, and cater to a mammoth market, both within the United States and globally. The company also aims to develop two core compounds by which further medication can develop and see delivered to patients undergoing chemotherapy. With its cash holding totaling above the $56 million figure, NCNA is capable of pushing through its development efforts for several years.

    NuCana’s Trial Discontinuation

    Earlier this year NCNA stock suffered quite a blow in the market with its price plummeting suddenly from almost $3 to less than $0.75. The reason for this fall was the announcement that NuCana would be discontinuing its biliary tract cancer treatment candidate, Acelarin. The market reacted so strongly because Acelarin was the most advanced candidate in the company’s development pipeline, and therefore had investors’ hopes most keenly tied to its progress. The decision came from the data monitoring committee, on the basis of a futility analysis that experts rigorously conducted on the findings.

    Conclusion

    Although the market had reacted quite negatively to the news of the Acelarin discontinuation, NCNA prospects appear strong overall. This is in large part due to the strong development pipeline, and a wide mix of FDA-approved treatments that are already under NuCana’s belt.